Zymeworks appoints Suzanne Monahan. Truist sets USD 34 target for Zymeworks stock

Published on 10/20/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zymeworks stock stood at EUR 22.80 on October 20, 2026. Second-quarter revenue was USD 3.23 million against USD 4.54 million expected.

Commercial leadership and upcoming results

Suzanne Monahan joined Zymeworks on October 19, 2026, to lead commercial operations for Theravance Biopharma.
Second-quarter revenue was USD 3.23 million against a USD 4.54 million consensus estimate.
Zymeworks stock stood at EUR 22.80 at 1:18 p.m. CEST at Lang & Schwarz on October 20, 2026.
Third-quarter results are scheduled for November 9, 2026.

ZYME, US98985Y1082, Illustration mit AI erstellt.

Zymeworks Inc. appointed Suzanne Monahan as senior vice president, commercial and general manager of Theravance Biopharma on October 19, 2026, while Truist set a USD 34.00 price target for Zymeworks stock on October 7, 2026. GlobeNewswire reported that Monahan will lead commercial strategy and execution for YUPELRI after Zymeworks acquired Theravance Biopharma. Markets Insider reported that Truist raised its target from USD 32.00 to USD 34.00 and maintained a Buy rating.

Commercial leadership follows the acquisition

Monahan brings more than 20 years of commercial leadership experience across pharmaceutical and medical device companies, according to GlobeNewswire. Her remit places YUPELRI, a once-daily nebulized treatment for chronic obstructive pulmonary disease, at the center of Zymeworks' commercial execution after the Theravance transaction.

What do the latest results signal?

Zymeworks' second-quarter 2026 revenue was USD 3.23 million, below the USD 4.54 million consensus estimate, while diluted earnings per share were a loss of USD 0.62 versus a consensus loss of USD 0.56, according to MarketBeat. Revenue declined 90.6 percent from the prior-year quarter, making the commercial contribution from the expanded portfolio an important operating question.

Three dated steps in the strategy

On September 28, 2026, Zymeworks set 2026 revenue guidance at USD 278 million to USD 292 million after the Theravance acquisition, as reported by FinanzNachrichten. On October 15, 2026, the company announced that it would release third-quarter results on November 9, 2026, according to Quiver Quantitative. On October 19, 2026, Zymeworks appointed Monahan to lead the Theravance commercial organization.

Results and conferences set the next dates

Zymeworks is scheduled to report third-quarter 2026 results after market close on November 9, 2026, and management is scheduled to attend the Wolfe Research Healthcare Conference on November 10, 2026, according to Quiver Quantitative. The company also listed Stifel's healthcare conference for November 11 and the Jefferies Global Healthcare Conference for November 17.

Stock price and portfolio scale

Zymeworks stock was trading at EUR 22.80 at Lang & Schwarz on October 20, 2026 at 1:18 p.m. CEST. The Nasdaq-listed company had a market capitalization of USD 1.8 billion and a 52-week range of USD 16.00 to USD 31.34 in the latest market snapshot. The further course of trading is shown by the continuously updated real-time quote of Zymeworks stock.